Evergreen Therapeutics Covid-19 drug candidate, EG-009A, will be trialled in a Phase II study after the company partnered with ICON on a clinical service agreement.

EG-009A is designed to treat moderate to severe Covid-19 pneumonia and hinder cytokine release syndrome (CRS), the company noted.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CRS is a key cause of death in various viral diseases, including influenza and SARS infections.

The multi-centre, randomised, double-blinded and controlled Phase II clinical trial will assess the efficacy of EG-009A in treating Covid-19.

To be carried out in the US, Brazil and Argentina, the first subjects are anticipated to be enrolled in August this year. Evergreen plans to conclude the trial by mid-next year.

As per the US Food and Drug Administration (FDA) guidance, the Phase II trial design should focus on demonstrating clinically significance in lowering pulmonary failure and enhancing the survival rate in hospitalised Covid-19 patients.

As per the agreement, ICON will act as Evergreen’s clinical research organisation (CRO) to aid in managing the trial. ICON will be responsible for the trial’s medical testing activities.

Evergreen Therapeutics CEO Dr David Du said: “Evergreen Therapeutics is pleased to partner with ICON, the world’s second-largest clinical trial service organisation, to serve as our CRO and arrange the Company’s Phase II clinical study for our Covid-19 injection drug candidate EG-009A.

“ICON was the clear partner of choice for Evergreen, given their extensive experience in the research and development of new drugs for the prevention and treatment of Covid-19.”

Over last year, Evergreen carried out research and obtained a patent to clinically develop EG-009A.

Furthermore, the company raised $15m in a Series A funding round in March this year. Evergreen will use the proceeds to finance the Phase II trial of EG-009A.

Evergreen has more than ten drug candidates in development and has a management team with research and development expertise.